GEN Exclusives

More »

GEN News Highlights

More »
Feb 24, 2009

PDS to Use Merck Eprova's Cationic Lipid to Enhance Preclinical Compounds

PDS to Use Merck Eprova's Cationic Lipid to Enhance Preclinical Compounds

PDS gets license to use Merck Eprova's chiral lipid

  • PDS Biotechnology obtained a license for use of Merck Eprova's chiral lipid DOTAP chloride in its immunotherapies, which are in preclinical development. PDS will use the cGMP produced enantiomerically pure DOTAP chloride for these clinical candidates as well as eventually in commercial production.

    Under the deal, PDS will own the intellectual property rights to products incorporating the lipids for immunotherapeutic applications.

    PDS Biotechnology’s drug candidates are being developed on its Versamune nanoparticle technology. Furthest along is Versamune-HPV, which has demonstrated promise in curing HPV infection and HPV-related cancer in preclinical studies, says PDS. Another compound is called Versamune-Melanoma.

    Based on in vivo and in vitro efficacy data, PDS Biotechnology was awarded grants by the NCI to develop Versamune-HPV and Versamune-Melanoma.

    PDS' Versamune nanotechnology facilitates the uptake of disease-associated protein and peptide antigens by the antigen-presenting cells of the immune system. Simultaneously, it reportedly acts as a strong immune system activator without the inflammatory side effects induced by current adjuvants.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?